安进公司宣布,其Tepezza皮下注射剂针对中重度活动性甲状腺眼病成人患者的三期临床试验取得积极顶线结果。
安进公司宣布,其Tepezza皮下注射剂针对中重度活动性甲状腺眼病成人患者的三期临床试验取得积极顶线结果。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.